Clinical experience with recombinant somatropin: German collaborative study.
A multicentre trial with recombinant somatropin was initiated in West Germany in early 1986. Acceptance of patients to the study was determined according to criteria outlined in a detailed study protocol. A total of 62 patients with GH deficiency has now been treated with recombinant somatropin for a minimum of 12 months. Of these, 34 were previously untreated and 28 had previously received pituitary GH. Recombinant somatropin, 12 IU/m2/week, was administered subcutaneously, divided into six doses. Height velocities increased from 3.4 cm/year (pretreatment) to 10.4 cm/year in the previously untreated group, and from 6.0 cm/year during the last year on pituitary GH to 8.3 cm/year for the previously treated patients. Tolerance of recombinant somatropin was good, and no anti-GH antibodies were detected in any of the patients.
Bierich
J R
JR
Department of Paediatrics, University of Tübingen, West Germany.
D000293:Adolescent; D001827:Body Height / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D005260:Female; D005860:Germany, West; D013006:Growth Hormone / Q000172:deficiency*; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D013006:Growth Hormone